GlucoTrack (NASDAQ:GCTK) Stock Price Down 7.5% – Here’s What Happened

GlucoTrack, Inc. (NASDAQ:GCTK)’s stock price dropped 7.5% on Monday . The company traded as low as $6.27 and last traded at $6.29. Approximately 9,069 shares changed hands during trading, a decline of 99% from the average daily volume of 669,445 shares. The stock had previously closed at $6.80.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

GlucoTrack Trading Down 7.5%

The company has a 50-day moving average of $6.35 and a 200 day moving average of $6.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.27 and a quick ratio of 3.27. The company has a market cap of $5.73 million, a PE ratio of -0.18 and a beta of 0.24.

Hedge Funds Weigh In On GlucoTrack

A hedge fund recently raised its stake in GlucoTrack stock. Bank of America Corp DE boosted its position in GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,089 shares of the company’s stock after purchasing an additional 4,085 shares during the period. Bank of America Corp DE owned approximately 0.85% of GlucoTrack worth $25,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.92% of the company’s stock.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.